Thursday, June 7, 2012
A team from The University of Alabama at Birmingham has
proposed a new strategy to treat cast nephropathy, a common renal complication
of multiple myeloma.1 The approach involves using a cyclic peptide
therapeutic to block the interaction between tumor-derived immunoglobulin
light chain proteins and an abundant urine protein called uromodulin.
The team now needs to optimize the peptide's oral bioavailability.
Role of THP
L. SciBX 5(23);
doi:10.1038/scibx.2012.589 Published online June 7, 2012
1. Ying, W.-Z. et al. J. Clin.
Invest.; published online April 9,
2012; doi:10.1172/JCI46490 Contact: Paul W.
Sanders, The University of Alabama at Birmingham, Birmingham, Ala. e-mail: email@example.com
2. Hutchison, C.A. et al. Nat. Rev.
Nephrol. 8, 43-51 (2011)
3. Sanders, P.W. &
Booker, B.B. J. Clin. Invest. 89, 630-639 (1992)
AND INSTITUTIONS MENTIONED
Ra Pharmaceuticals Inc., Cambridge, Mass.
The University of Alabama at Birmingham, Birmingham, Ala.